NCT06553625 Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS
| NCT ID | NCT06553625 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boston Scientific Corporation |
| Condition | Parkinson Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-01-29 |
| Primary Completion | 2035-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-01-29 with a primary completion date of 2035-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery.
Eligibility Criteria
Inclusion Criteria: * Study candidate is scheduled to be treated with a commercially approved Boston Scientific RF system for pain or for CNS applications per local Directions for Use (DFU) * Signed a valid, IRB/EC/REB-approved informed consent form Exclusion Criteria: * Meets any contraindications per locally applicable Directions for Use (DFU) * Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments
Contact & Investigator
Natalie M Bloom Lyons, M.A.
STUDY DIRECTOR
Boston Scientific Corporation
Frequently Asked Questions
Who can join the NCT06553625 clinical trial?
This trial is open to participants of all sexes, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06553625 currently recruiting?
Yes, NCT06553625 is actively recruiting participants. Contact the research team at BSNClinicalTrials@bsci.com for enrollment information.
Where is the NCT06553625 trial being conducted?
This trial is being conducted at Cologne, Germany, Düsseldorf, Germany, Würzburg, Germany, London, United Kingdom.
Who is sponsoring the NCT06553625 clinical trial?
NCT06553625 is sponsored by Boston Scientific Corporation. The principal investigator is Natalie M Bloom Lyons, M.A. at Boston Scientific Corporation. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.